talquetamab will increase the degree or influence of ergotamine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. Talquetamab causes cytokine launch syndrome (CRS) that may suppress activity of CYP enzymes, resulting in enhanced exposure of CYP substrates.ergotamine will raise the degree or impact of tazemetosta